We recently published an article titled Why These 10 Firms Nosedived Today.In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank's decision to keep interest rates unchanged. On Wednesday afternoon, the Federal Reserve kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impacts of President Donald Trump’s tariff policies. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent. Beyond the major indices, bucked a broader market optimism as investors sold off on a series of disappointing news. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Sarepta Therapeutics, Inc. (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Sarepta Therapeutics, Inc. (NASDAQ:SRPT) nosedived by 21.45 percent on Wednesday to end at $36.72 apiece after reporting a disappointing earnings performance in the first quarter of the year. During the period, the company swung to a net loss of $447.5 million from a $36.1 million net income in the same period last year, despite revenues jumping by 80 percent to $744.9 million from $413.5 million year-on-year, with the increase primarily driven by a $241-million higher net product revenue from Elevidys—a gene therapy for Duchenne muscular dystrophy (DMD)—as a result of its expanded label approval in June 2024. Looking ahead, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said it expects lower revenues for full-year 2025, at $2.3 billion to $2.6 billion versus the $2.9 billion to $3.1 billion as expected previously. Earlier this year, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported that a young patient succumbed to acute liver failure after receiving the Sarepta Elevidys therapy. While the risk has already been flagged on the Elevidys label, acute liver injuries leading to death have not been previously reported in clinical testing or real-world use of Elevidys. Overall SRPT ranks 2nd on our list of Wednesday's worst performers. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. Story Continues READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...